IDEX Corporation’s Fourth Quarter 2025 Earnings: Anticipated Highlights

IDEX Corporation: Company Overview

Headquartered in Northbrook, Illinois, IDEX Corporation (IEX) is recognized as a global leader in applied solutions, specializing in the design and production of essential components that play a vital role in various industrial operations.

With a market value of approximately $13.4 billion, IDEX’s expertise covers areas such as fluid management, precision manufacturing, and safety technologies. Its diverse product lineup includes pumps, valves, meters, processing equipment, sealing systems, and advanced rescue devices.

Latest Headlines from Barchart

Upcoming Earnings and Analyst Expectations

Investors are closely watching for IDEX’s fourth-quarter fiscal 2025 earnings report, set for Tuesday, February 3. Analysts anticipate diluted earnings per share (EPS) of $2.04, mirroring results from the same quarter last year. Impressively, IDEX has exceeded EPS forecasts for the past four quarters, further establishing its reliability.

Looking ahead, projections for fiscal 2025 suggest diluted EPS will remain steady at $7.89, with a projected 5.3% increase to $8.31 in fiscal 2026.

Stock Performance Compared to Benchmarks

Over the last 52 weeks, IDEX shares have fallen by 12.7%, underperforming broader indices. However, the stock has gained 1.6% since the start of the year. In comparison, the S&P 500 Index ($SPX) rose 16.2% during the same period, though its year-to-date gains have been more modest.

At the sector level, the State Street Industrial Select Sector SPDR ETF (XLI) advanced 20.4% over the past year and is up 3.1% year-to-date, both figures surpassing IDEX’s performance.

Recent Financial Highlights

Despite trailing the market, IDEX delivered a notable boost on October 29, 2025, when its stock surged 3.9% intraday following the release of its third-quarter fiscal 2025 results. The company reported revenue of $878.7 million for the quarter, a 10.1% year-over-year increase and ahead of analyst expectations of $861.1 million. Adjusted EPS climbed 6.8% to $2.03, beating the consensus estimate of $1.93.

Management credited this strong performance to growth in Health & Science Technologies and robust demand from sectors such as data centers, municipal water infrastructure, and pharmaceuticals. CEO Eric Ashleman highlighted the company’s “8020 philosophy,” which has improved operational efficiency, accelerated the integration of acquisitions, and enhanced contributions from material science and smart water initiatives.

Analyst Ratings and Price Targets

Given these solid fundamentals, Wall Street maintains a “Moderate Buy” consensus for IDEX shares, a rating that has remained stable over the past quarter. Out of 12 analysts, six recommend a “Strong Buy,” one suggests a “Moderate Buy,” and five rate the stock as “Hold.”

The average price target stands at $192.27, indicating a potential upside of 6.3%. The highest target among analysts is $210, which would represent a 16.2% increase from current levels.